Medincell partner wins FDA approval for WELTRUZA
Medincell said its partner Teva announced U.S. FDA approval of WELTRUZA, an extended-release injectable suspension of olanzapine for adults with schizophrenia. Teva plans to make the treatment available in the United States in the coming weeks.